Non-alcoholic fatty liver disease as a visceral manifestation of metabolic syndrome
Gastroenterologe, ISSN: 1861-969X, Vol: 8, Issue: 6, Page: 517-524
2013
- 3Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Non-alcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in developed countries. It is the third most common indication for liver transplantation in the United States. NAFLD affects children and adults. It is considered to be the hepatic manifestation of metabolic syndrome. Clinical case histories validated the progression of NFALD to steatohepatitis and frank liver cirrhosis. Patients with steatohepatitis are at increased risk to suffer from cardiovascular disease and even cancer. Liver biopsy currently remains the gold standard for the diagnosis. © 2013 Springer-Verlag Berlin Heidelberg.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84888166920&origin=inward; http://dx.doi.org/10.1007/s11377-013-0823-x; http://link.springer.com/10.1007/s11377-013-0823-x; http://link.springer.com/content/pdf/10.1007/s11377-013-0823-x; http://link.springer.com/content/pdf/10.1007/s11377-013-0823-x.pdf; http://link.springer.com/article/10.1007/s11377-013-0823-x/fulltext.html; https://dx.doi.org/10.1007/s11377-013-0823-x; https://link.springer.com/article/10.1007/s11377-013-0823-x
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know